Should cosentyx users delay vaccinations?

What happens to Cosentyx users who get vaccinated while taking it?

Cosentyx (secukinumab) works by blocking interleukin-17A, a cytokine that helps drive inflammation in conditions like psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. It also affects the immune system's ability to respond to infections. [1]

Cosentyx users who get vaccinated while on treatment can still produce antibodies, but their response may be weaker than normal. Live vaccines should generally be avoided because the drug's mechanism raises infection risk if the vaccine strain turns active. Non-live vaccines remain safe, but doctors often recommend checking antibody levels afterward to confirm protection. [2]

How do doctors decide whether to delay vaccinations?

Doctors weigh the infection risk from postponing vaccination against the reduced immune response from receiving it under Cosentyx. For routine adult vaccines such as influenza or pneumococcal, timing often gets adjusted around treatment cycles. For required immunizations before starting Cosentyx, physicians frequently recommend waiting four weeks after vaccination before initiating the drug. [3]

When does Cosentyx interfere with vaccine response?

Cosentyx interferes with vaccine response mainly during active treatment. Interference begins once the drug reaches therapeutic levels after the first few doses. Interference ends when secukinumab levels fall below effective range, but that time is difficult to calculate because its half-life spans weeks. [4]

What happens if a user gets a live vaccine while on Cosentyx?

A user who receives a live vaccine under Cosentyx may face increased risk of vaccine-strain infection because secukinumab suppresses parts of the immune system needed to control it. Data from clinical trials and post-marketing reports show higher rates of infections overall, but vaccine-specific cases remain rare. [1]

What alternatives exist for Cosentyx users needing vaccines?

Alternatives include holding Cosentyx for a temporary period before vaccination, switching to a different biologic that has less interference with vaccines, or testing post-vaccination antibody titers to verify protection. Some patients receive vaccines before any biologic treatment begins. [2][3]

Why are companies challenging patents on Cosentyx?

Why are companies challenging patents on Cosentyx?

Cosentyx is protected by patents covering the secukinumab molecule itself and its use in certain diseases. Companies challenge these patents to gain entry into the market before natural expiry. The earliest reported challenges came in 2017. [5]

When does Cosentyx patent expire?

When does Cosentyx patent expire?

Cosentyx's composition of matter patent expires in 2030 in the United States. The main use patents also extend into the 2030s. [5]

Can biosimilars enter before patent expiry?

Can biosimilars enter after patent expiry?

Cosentyx biosimilars are not yet approved in the United States. The earliest possible entry would occur after 2030. [5]